Activation of the Alternative RAS through the Mas and MrgD receptors leads to a variety of biologic effects and the potential to develop drug therapies for a wide range of diseases. These diseases include, but are not limited to, those characterized by tissue fibrosis and endothelial damage. Constant has discovered a number of proprietary small molecules that act as Mas/MrgD agonists, and we have identified relationships between the balance of Mas and MrgD dependent activity (“receptor fingerprint”) and these biologic effects. These small molecule agonists will be developed as treatments for both widespread and rare diseases which currently have few available treatments.
